Nkarta, Inc.
NASDAQ:NKTXBiotechnology
+$0.09 today
- Market cap
- $82.37M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
Volume 0.81M
Average 0.75M
NKTX EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Nkarta, Inc.NASDAQ: NKTX
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.37, compared with -$0.43 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.34.
Context
- EPS (Diluted) grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 3 analysts of -$1.45 (-2.6%) for the fiscal year ending Dec 2026, a slowdown from the +11.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.37+0.0% QoQ
- Last fiscal yearDec 2025
- -$1.41+11.9% YoY
- LTMMar 2026
- -$1.34+11.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +14.0% | -17.4% | -31.4 pp |
| 1 year | +11.9% | -2.6% | -14.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.41) USD
- Year-over-year change
- +11.9%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.41) | +11.9% |
| FY2024 | 2024-12-31 | (1.60) | +33.3% |
| FY2023 | 2023-12-31 | (2.40) | +8.0% |
| FY2022 | 2022-12-31 | (2.61) | +0.4% |
| FY2021 | 2021-12-31 | (2.62) | — |
EPS (Diluted) vs competitors
How NKTX compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +11.3% is the 5th highest of 8, against a peer median of +26.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$1.09 USD | +26.8% | — | |
| LTM Mar 2026 | -$1.19 USD | +6.4% | — | |
| LTM Mar 2026 | -$1.34 USD | +11.3% | — | |
| LTM Mar 2026 | -CHF 1.56 CHF | +9.3% | — | |
| LTM Mar 2026 | -$2.1 USD | +32.9% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | -$2.36 USD | +41.7% | — |
| LTM Mar 2026 | -$4.58 USD | +66.8% | — | |
| LTM Mar 2026 | -$838.86 USD | -2659.4% | — | |
| Peer median (excluding NKTX) | — | +26.8% | — | |
Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 5.87M | 0 | 9.19M |
| Gross Profit | 0 | 0 | (5.87M) | 0 | (9.19M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 63.41M | 90.9M | 90.9M | 96.74M | 90.43M |
| Selling, General & Admin | 23.02M | 28.06M | 34.88M | 31.45M | 31.57M |
| Operating Expenses | 86.43M | 118.96M | 125.78M | 128.19M | 112.01M |
| Depreciation & Amortization | 1.76M | 2.64M | 5.87M | 9.15M | 9.19M |
| EBITDA | (84.32M) | (105.61M) | (120.48M) | (99.64M) | (94.89M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (86.43M) | (118.96M) | (131.65M) | (128.19M) | (121.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 370K | 5.59M | 14.11M | 19.32M | 15.49M |
| Interest Expense | 0 | 5.59M | 0 | 0 | 0 |
| Other Income / Expenses | 354K | 5.12M | 14.15M | 19.4M | 17.12M |
| Income Before Tax | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.62) | (2.61) | (2.40) | (1.60) | (1.41) |
| EPS (Diluted) | (2.62) | (2.61) | (2.40) | (1.60) | (1.41) |
| Weighted Avg Shares | 32.86M | 43.63M | 49.01M | 67.87M | 73.99M |
| Weighted Avg Shares (Diluted) | 32.86M | 43.63M | 49.01M | 67.87M | 73.99M |
Nkarta, Inc.
NASDAQ:NKTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.